(19)
(11) EP 4 028 033 A1

(12)

(43) Date of publication:
20.07.2022 Bulletin 2022/29

(21) Application number: 20862242.3

(22) Date of filing: 11.09.2020
(51) International Patent Classification (IPC): 
A61K 35/17(2015.01)
C12N 5/0783(2010.01)
 C07K 14/725(2006.01)
C12N 15/62(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 35/17; A61P 35/00; C07K 14/7051; C12N 5/0636; C12N 2510/00; C12N 15/907; C12N 2310/20; C12N 15/1138; C07K 2319/03
(86) International application number:
PCT/US2020/050503
(87) International publication number:
WO 2021/050948 (18.03.2021 Gazette 2021/11)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 12.09.2019 US 201962899563 P
07.02.2020 US 202062971682 P

(71) Applicant: TCR2 Therapeutics Inc.
Cambridge, Massachusetts 02142 (US)

(72) Inventors:
  • BAEUERLE, Patrick
    Cambridge, Massachusetts 02142 (US)
  • HOFMEISTER, Robert
    Cambridge, Massachusetts 02142 (US)
  • GETTS, Daniel
    Cambridge, Massachusetts 02142 (US)
  • GUTIERREZ, Dario
    Cambridge, Massachusetts 02142 (US)
  • KIEFFER-KWON, Philippe
    Cambridge, Massachusetts 02142 (US)
  • DONAGHEY, Julie
    Cambridge, Massachusetts 02142 (US)

(74) Representative: Leonard, Thomas Charles et al
Kilburn & Strode LLP Lacon London 84 Theobalds Road
London WC1X 8NL
London WC1X 8NL (GB)

   


(54) COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS